Oral Valganciclovir Initiated Beyond 1 Month of Age as Treatment of Sensorineural Hearing Loss Caused by Congenital Cytomegalovirus Infection: A Randomized Clinical Trial
David W. Kimberlin, Inmaculada Aban, Kalyani Peri, Javier K. Nishikawa, Jolanta Bernatoniene, Marieke Emonts, Nigel Klein, Alasdair Bamford, Roberta L. DeBiasi, Saul N. Faust, Christine E. Jones, Paddy McMaster, Mary T. Caserta, Amina Ahmed, Mike Sharland, Gail J. Demmler‐Harrison, Scott Hackett, Pablo J. Sánchez, Fiona Shackley, Dominic F. Kelly, Penelope H. Dennehy, Gregory A. Storch, Richard J. Whitley, Paul Griffiths
Topics & Concepts
ValganciclovirMedicineSensorineural hearing lossPlaceboRandomized controlled trialHearing lossCytomegalovirusInternal medicinePediatricsGanciclovirAudiologyHuman cytomegalovirusHerpesviridaeViral diseaseImmunologyVirusAlternative medicinePathologyCytomegalovirus and herpesvirus researchHerpesvirus Infections and TreatmentsOcular Diseases and Behçet’s Syndrome